Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]-Reference-Cited by-同舟云学术

Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]

Published:2023-03 Issue: Volume:70 Page:51-62
ISSN:2530-0180
Container-title:Endocrinología, Diabetes y Nutrición (English ed.)
language:en
Short-container-title:Endocrinología, Diabetes y Nutrición (English ed.)

Author:

Pedro-Botet Juan,Barrios Vivencio,Sánchez-Margalet Víctor,Tamargo Juan,Arrieta Francisco,Gámez José Mª,Gimeno-Orna José Antonio,Escobar Carlos,Gómez-Doblas Juan José,Pérez Antonio

Publisher

Elsevier BV

Subject

Nutrition and Dietetics,Endocrinology,Endocrinology, Diabetes and Metabolism

Reference97 articles.

1. GBD-NHLBI-JACC Global Burden of Cardiovascular Diseases Writing Group. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study;Roth;J Am Coll Cardiol,2020

2. Conceptual framework for addressing residual atherosclerotic cardiovascular disease risk in the era of precision medicine;Patel;Circulation,2018

3. Reducing residual cardiovascular risk with novel therapies;Davidson;Curr Opin Lipidol,2020

4. Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies;Lawler;Eur Heart J,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer;Clinical Drug Investigation;2024-07-31